This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Geurts, J. M. W. Articles by Van de Ven, W. J. M. Search for Related Content PubMed PubMed Citation Articles by Geurts, J. M. W. Articles by Van de Ven, W. J. M.

Expression of Reciprocal Hybrid Transcripts of HMGIC and FHIT in a Pleomorphic Adenoma of the Parotid Gland¹

Laboratory for Molecular Oncology, Center for Human Genetics, University of Leuven and Flanders Interuniversity Institute for Biotechnology, Herestraat 49, B-3000 Leuven, Belgium [J. M. W. G., E. F. P. M. S., W. J. M. V.], and Laboratory of Cancer Genetics, Department of Pathology, Göteborg University, Göteborg, Sweden [E. R., G. S.]

The developmentally regulated HMGIC gene, which encodes an architectural transcription factor, has recently been linked to the pathogenesis of benign solid tumors with chromosome aberrations involving 12q13–15. Among these tumors are pleomorphic adenoma of the salivary glands, lipoma, uterine leiomyoma, hamartomas of the breast and lung, fibroadenoma of the breast, angiomyxoma, and endometrial polyps. For most tumor types, however, the translocation partners are variable. At present, no translocation partner genes of HMGIC are known for pleomorphic adenomas. Here, we report that in a primary pleomorphic adenoma of the parotid gland, the FHIT gene, which spans the chromosome 3p14.2 fragile site FRA3B, and is frequently disrupted in tumors, acts as a fusion partner of HMGIC. In addition to normal HMGIC and FHIT transcripts, an HMGIC/FHIT hybrid transcript as well as its reciprocal counterpart, FHIT/HMGIC, were found to be expressed by reverse transcription-PCR. The results establish the concurrent disruption of two tumor-associated genes in a benign tumor.

¹ This work was supported in part by the National Fonds voor Wetenschappelijk Onderzoek, the Geconcerteerde Onderzoekacties 1992–1996, the Flanders Interuniversity Institute for Biotechnology, the Biomed 1 Concerted Action "Molecular Cytogenetics of Solid Tumors" (CT92-0156), the ASLK Programma voor Kankeronderzoek, the Swedish Cancer Society, and the IngaBritt and Arne Lundbergs Research Foundation. J. M. W. G. is a Research Assistant of the Nationaal Fonds voor Wetenschappelijk Onderzoek (Kom op tegen Kanker, Belgium).

² To whom requests for reprints should be addressed. Phone: 32-16-345987; Fax: 32-16-346073; E-mail: wim.vandeven@med.kuleuven.ac.be.

Received 9/20/96. Accepted 11/20/96.

This article has been cited by other articles:

				S. Di Palma, M. B K Lambros, K. Savage, C. Jones, A. Mackay, T. Dexter, M. Iravani, K. Fenwick, A. Ashworth, and J. S Reis-Filho Oncocytic change in pleomorphic adenoma: molecular evidence in support of an origin in neoplastic cells J. Clin. Pathol., May 1, 2007; 60(5): 492 - 499. [Abstract] [Full Text] [PDF]

				C. Mayr, M. T. Hemann, and D. P. Bartel Disrupting the Pairing Between let-7 and Hmga2 Enhances Oncogenic Transformation Science, March 16, 2007; 315(5818): 1576 - 1579. [Abstract] [Full Text] [PDF]

				M. R. Zaidi, Y. Okada, and K. K. Chada Misexpression of Full-length HMGA2 Induces Benign Mesenchymal Tumors in Mice. Cancer Res., August 1, 2006; 66(15): 7453 - 7459. [Abstract] [Full Text] [PDF]

				T. W. Glover, M. F. Arlt, A. M. Casper, and S. G. Durkin Mechanisms of common fragile site instability Hum. Mol. Genet., October 15, 2005; 14(suppl_2): R197 - R205. [Abstract] [Full Text] [PDF]

				H Nagel, R Laskawi, H Eiffert, and T Schlott Analysis of the tumour suppressor genes, FHIT and WT-1, and the tumour rejection genes, BAGE, GAGE-1/2, HAGE, MAGE-1, and MAGE-3, in benign and malignant neoplasms of the salivary glands Mol. Pathol., August 1, 2003; 56(4): 226 - 231. [Abstract] [Full Text] [PDF]

				M Pia-Foschini, J S Reis-Filho, V Eusebi, and S R Lakhani Salivary gland-like tumours of the breast: surgical and molecular pathology J. Clin. Pathol., July 1, 2003; 56(7): 497 - 506. [Abstract] [Full Text] [PDF]

				S. Corbin, M. E. Neilly, R. Espinosa III, E. M. Davis, T. W. McKeithan, and M. M. Le Beau Identification of Unstable Sequences within the Common Fragile Site at 3p14.2: Implications for the Mechanism of Deletions within Fragile Histidine Triad Gene/Common Fragile Site at 3p14.2 in Tumors Cancer Res., June 1, 2002; 62(12): 3477 - 3484. [Abstract] [Full Text] [PDF]

				D. Bodmer, M. Eleveld, E. Kater-Baats, I. Janssen, B. Janssen, M. Weterman, E. Schoenmakers, M. Nickerson, M. Linehan, B. Zbar, et al. Disruption of a novel MFS transporter gene, DIRC2, by a familial renal cell carcinoma-associated t(2;3)(q35;q21) Hum. Mol. Genet., March 1, 2002; 11(6): 641 - 649. [Abstract] [Full Text] [PDF]

				E. Roijer, A. Nordkvist, A.-K. Strom, W. Ryd, M. Behrendt, J. Bullerdiek, J. Mark, and G. Stenman Translocation, Deletion/Amplification, and Expression of HMGIC and MDM2 in a Carcinoma ex Pleomorphic Adenoma Am. J. Pathol., February 1, 2002; 160(2): 433 - 440. [Abstract] [Full Text] [PDF]

				H. Ishii, K. R. Dumon, A. Vecchione, L. Y. Y. Fong, R. Baffa, K. Huebner, and C. M. Croce Potential Cancer Therapy With the Fragile Histidine Triad Gene: Review of the Preclinical Studies JAMA, November 21, 2001; 286(19): 2441 - 2449. [Abstract] [Full Text] [PDF]

				L. J. Wood, J. F. Maher, T. E. Bunton, and L. M. S. Resar The Oncogenic Properties of the HMG-I Gene Family Cancer Res., August 1, 2000; 60(15): 4256 - 4261. [Abstract] [Full Text]

				G. C. Banks, B. Mohr, and R. Reeves The HMG-I(Y) A·T-hook Peptide Motif Confers DNA-binding Specificity to a Structured Chimeric Protein J. Biol. Chem., June 4, 1999; 274(23): 16536 - 16544. [Abstract] [Full Text] [PDF]

				G. Giannini, L. Di Marcotullio, E. Ristori, M. Zani, M. Crescenzi, S. Scarpa, G. Piaggio, A. Vacca, F. A. Peverali, F. Diana, et al. HMGI(Y) and HMGI-C Genes Are Expressed in Neuroblastoma Cell Lines and Tumors and Affect Retinoic Acid Responsiveness Cancer Res., May 1, 1999; 59(10): 2484 - 2492. [Abstract] [Full Text] [PDF]

				A.-K. Astrom, M. L. Voz, K. Kas, E. Roijer, B. Wedell, N. Mandahl, W. V. de Ven, J. Mark, and G. Stenman Conserved Mechanism of PLAG1 Activation in Salivary Gland Tumors with and without Chromosome 8q12 Abnormalities: Identification of SII as a New Fusion Partner Gene Cancer Res., February 1, 1999; 59(4): 918 - 923. [Abstract] [Full Text] [PDF]

				R. M. Gemmill, J. D. West, F. Boldog, N. Tanaka, L. J. Robinson, D. I. Smith, F. Li, and H. A. Drabkin The hereditary renal cell carcinoma 3;8 translocation fuses FHIT to a patched-related gene, TRC8 PNAS, August 4, 1998; 95(16): 9572 - 9577. [Abstract] [Full Text] [PDF]